Sohu Pharmaceutical | Lilly, Novo and Norders will divide 50 billion weight loss pills in 2030

Produced | Sohu Health

Author | Zhou Yichuan

Edit | Yuan Yue

The FierePharma website reported that Morgan Stanley recently released a customer report saying that companies such as Lilly, Novo Norders divided the global obesity therapy market worth more than 50 billion US dollars in 2030.

Obesity was officially classified as chronic diseases by the American Medical Association and the European Commission in 2013. The priority of obesity treatment may be higher than other chronic diseases. Preventive treatment will turn to the upstream instead of downstream diabetes and heart disease. Affected by this, the global obesity pharmaceutical market will reach $ 54 billion in 2030.

Last year, Nuo and Nord's Smeglugan peptide obtained obesity treatment indications. In the third quarter of this year, the prevention effect of drugs on heart disease, stroke and death will be published. Clinical trial results. Some experts commented that the weight loss data of these two drugs is equivalent to the weight loss surgery, which avoids the risk of surgery and postoperative complications, and undoubtedly provides updated clinical choices.

Social media has now formed a cycle of increased demand for weight loss drugs. Over time, 25%of obese people will consult a doctor for treatment, and 55%of them may meet drug indications. In 2030, the two companies may have a 40%market, and some large pharmaceutical companies with cardiac metabolic products may challenge this field.

It is important to pay attention to the insurance payment of weight loss pills still has many obstacles. Who is applicable, whether long -term treatment is required, and other issues require policy makers and doctors. Affected by it.

- END -